Generic Medicine Info
Indications and Dosage
Allergic conditions
Adult: >12 yr and >50 kg: 60-120 mg in the morning or 60 mg bid. Max: 120 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<40 Half the usual daily dose
Special Precautions
Child and elderly. Avoid in patients with cardiac or significant hepatic disease, electrolyte imbalance, or known or suspected prolongation of the QT interval. Lactation, pregnancy.
Adverse Reactions
Anxiety, palpitations, insomnia, mild GI distubances, erythema multiforme and galactorrhoea.
Potentially Fatal: Ventricular arrhythmias including torsades de pointes. Palpitations, dizziness, syncope or convulsions may indicate arrhythmias. Hepatitis.
Drug Interactions
Potentially Fatal: Increased risk of ventricular arrhythmia with triazole and imidazole antifungals, macrolide antibacterials, streptogramin antibacterials, SSRI, HIV-protease inhibitors and non-nucleoside reverse transcriptase inhibitors, arrhythmogenic drugs, diuretics, astemizole and zileutron.
Food Interaction
Grapefruit juice may inhibit the metabolism of terfenadine.
Mechanism of Action: Terfenadine, a piperidine derivative, is a non-sedating H1 receptor antagonist antihistamine.
Absorption: Rapidly absorbed from GI tract. Peak plasma concentrations: within 2 hr.
Distribution: Protein binding: 97% (terfenadine). Does not appear to cross the blood-brain barrier to significant extent. Limited amounts of fexofenadine, but not terfenadine detected in breast milk. Elimination half-life: 16-23 hr (terfenadine).
Metabolism: Prodrug and undergoes extensive first-pass metabolism in the liver to active (carboxylic acid derivative fexofenadine) and inactive metabolites.
Excretion: Excreted in the urine and faeces (traces of unchanged drug and metabolites)
MIMS Class
Antihistamines & Antiallergics
Disclaimer: This information is independently developed by MIMS based on Terfenadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in